Boston Partners Boosts Position in Lantheus Holdings, Inc. $LNTH

Boston Partners lifted its position in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 30.5% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 576,362 shares of the medical equipment provider’s stock after buying an additional 134,781 shares during the quarter. Boston Partners owned approximately 0.85% of Lantheus worth $46,432,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of the company. Westfield Capital Management Co. LP increased its holdings in Lantheus by 2.2% during the 1st quarter. Westfield Capital Management Co. LP now owns 1,589,145 shares of the medical equipment provider’s stock worth $155,101,000 after acquiring an additional 34,052 shares during the period. Reinhart Partners LLC. grew its position in shares of Lantheus by 16.4% during the 2nd quarter. Reinhart Partners LLC. now owns 1,403,659 shares of the medical equipment provider’s stock valued at $114,905,000 after purchasing an additional 197,719 shares in the last quarter. Dimensional Fund Advisors LP increased its holdings in shares of Lantheus by 2.3% in the first quarter. Dimensional Fund Advisors LP now owns 1,378,536 shares of the medical equipment provider’s stock worth $134,534,000 after purchasing an additional 31,454 shares during the period. Swedbank AB raised its position in shares of Lantheus by 11.0% in the first quarter. Swedbank AB now owns 1,228,743 shares of the medical equipment provider’s stock worth $119,925,000 after buying an additional 121,500 shares in the last quarter. Finally, Nuveen LLC bought a new stake in Lantheus during the first quarter valued at $55,941,000. 99.06% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on the company. The Goldman Sachs Group set a $77.00 target price on Lantheus and gave the stock a “neutral” rating in a research note on Wednesday, October 8th. Mizuho decreased their price objective on shares of Lantheus from $120.00 to $70.00 and set an “outperform” rating on the stock in a research report on Thursday, August 7th. Weiss Ratings downgraded shares of Lantheus from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Saturday, October 25th. TD Cowen dropped their target price on shares of Lantheus from $95.00 to $80.00 and set a “buy” rating for the company in a research report on Monday, September 15th. Finally, B. Riley decreased their price target on shares of Lantheus from $109.00 to $84.00 and set a “buy” rating on the stock in a report on Tuesday, September 16th. Four equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $74.17.

Lantheus Stock Performance

NASDAQ LNTH opened at $58.75 on Friday. The company has a 50-day simple moving average of $54.42 and a two-hundred day simple moving average of $64.40. Lantheus Holdings, Inc. has a 12-month low of $47.25 and a 12-month high of $111.29. The firm has a market cap of $3.90 billion, a price-to-earnings ratio of 15.63 and a beta of 0.04. The company has a quick ratio of 4.07, a current ratio of 4.29 and a debt-to-equity ratio of 0.49.

Lantheus (NASDAQ:LNTH) last released its quarterly earnings data on Tuesday, May 17th. The medical equipment provider reported $0.05 EPS for the quarter. The firm had revenue of $92.51 million for the quarter. Lantheus had a return on equity of 34.06% and a net margin of 17.82%. On average, equities analysts forecast that Lantheus Holdings, Inc. will post 6.01 EPS for the current year.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.